Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Janku

Showing results (251-260 of 277) with videos related to

Pageof 28
Sort By:
American Journal of Clinical Pathology|October 22, 2015
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencingSinchita Roy-Chowdhuri, Debora de Melo Gagliato, Mark J Routbort, et al.
Journal for Immunotherapy of Cancer|October 24, 2020
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom InventoryTito Mendoza, Ajay Sheshadri, Mehmet Altan, et al.
The Lancet. Gastroenterology & Hepatology|July 14, 2019
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 studyMaeve A Lowery, Howard A Burris, Filip Janku, et al.
Cancer|November 2, 2018
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignanciesMinny Bhatty, Shumei Kato, Sarina A Piha-Paul, et al.
JCO Precision Oncology|August 27, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and PFilip Janku, Opeyemi A Jegede, Shannon L Puhalla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin LymphomaFilip Janku, Haeseong Park, S Greg Call, et al.
Blood|March 12, 2016
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineagesJean-François Emile, Oussama Abla, Sylvie Fraitag, et al.
Blood|March 19, 2020
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular eraGaurav Goyal, Mark L Heaney, Matthew Collin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2021
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyRonald S Go, Eric Jacobsen, Robert Baiocchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2021
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid TumorsAntje Wick, Oliver Bähr, Martin Schuler, et al.
Pageof 28

Showing results (251-260 of 277) with videos related to

Sort By:
Pageof 28
American Journal of Clinical Pathology|October 22, 2015
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencingSinchita Roy-Chowdhuri, Debora de Melo Gagliato, Mark J Routbort, et al.
Journal for Immunotherapy of Cancer|October 24, 2020
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom InventoryTito Mendoza, Ajay Sheshadri, Mehmet Altan, et al.
The Lancet. Gastroenterology & Hepatology|July 14, 2019
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 studyMaeve A Lowery, Howard A Burris, Filip Janku, et al.
Cancer|November 2, 2018
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignanciesMinny Bhatty, Shumei Kato, Sarina A Piha-Paul, et al.
JCO Precision Oncology|August 27, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and PFilip Janku, Opeyemi A Jegede, Shannon L Puhalla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin LymphomaFilip Janku, Haeseong Park, S Greg Call, et al.
Blood|March 12, 2016
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineagesJean-François Emile, Oussama Abla, Sylvie Fraitag, et al.
Blood|March 19, 2020
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular eraGaurav Goyal, Mark L Heaney, Matthew Collin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2021
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyRonald S Go, Eric Jacobsen, Robert Baiocchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2021
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid TumorsAntje Wick, Oliver Bähr, Martin Schuler, et al.
Pageof 28